TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00716417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: In each arm, BIBW 2992 dose will be escalated to determine MTD. Starting dose will be 20mg daily followed by 40 mg (with the option of an intermediary dose of 30 mg) then 50mg daily. Dose escalation will stop at 50 mg. No intra patient dose escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: low to high dose, daily
Study: NCT04570137

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary fiber supplementation
Description: 1. 16g/day: mix of 70% wheat-bran arabinoxylan and 30% oat-derived fiber (ß-glucan)~2. 16g/day: mix of 50% inulin and 50% oligofructose from chicory

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary fiber supplementation
Description: 1. 16g/day: mix of 70% wheat-bran arabinoxylan and 30% oat-derived fiber (ß-glucan)~2. 16g/day: mix of 50% inulin and 50% oligofructose from chicory
Study: NCT00707889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-869
Description: 12.5 mg QD, tablets taken orally days 1-14 of every 14-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: 10 mg/kg QD, IV on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: 85 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: 85 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: 85 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folinic acid
Description: 400 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folinic acid
Description: 400 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folinic acid
Description: 400 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: 400 mg/m2 IV bolus on Day 1 of each 14-day cycle; followed by 2400 mg/m2 IV infusion 46-48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: 400 mg/m2 IV bolus on Day 1 of each 14-day cycle; followed by 2400 mg/m2 IV infusion 46-48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: 400 mg/m2 IV bolus on Day 1 of each 14-day cycle; followed by 2400 mg/m2 IV infusion 46-48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-869
Description: 7.5 mg QD tablets taken orally days 1-14 of every 14-day cycle
Study: NCT03420118

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumour tissue collection
Description: Depending on the status of disease when participants join the study, a sample of tumour tissue may be collected from:~* A previous surgery for the disease,~* A biopsy for diagnosing the disease,~* Other surgical procedures done for clinical management or possible cancer related complications (e.g., bowel obstruction).~In addition:~* Patients undergoing pre-screening prior to diagnosis will have tumour sample collected at the time of surgery.~* At anytime participants require a biopsy as a part of their cancer care, a sample of that tumour tissue will be collected.~* New biopsies will be done to collect fresh tumour tissue each time participants' disease worsens.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draws
Description: Blood samples will be collected at the following different times points:~* All patient undergoing pre-screening for histological diagnosis will have blood samples collected.~* Before starting a new line of treatment for the disease,~* One week after starting a new line of treatment for the disease,~* During treatment, at each radiological assessment (imaging scan) that will be done to check the status of the disease,~* At the time the disease worsens or relapses (comes back)~* During observation/follow-up, at the time of any radiological assessments that will be done to check the status of the disease
Study: NCT00068692

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Undergo external beam radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Undergo external beam radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Undergo external beam radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Undergo external beam radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Undergo external beam radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Undergo external beam radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study: NCT00068692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV
Study: NCT01790724

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking exercise
Study: NCT02153320

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Sampling
Description: Single blood sample taken from subjects who had participated in the study 287615 (NCT00508833).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Sampling
Description: Single blood sample taken from subjects who had participated in the study 287615 (NCT00508833).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Sampling
Description: Single blood sample taken from subjects who had participated in the study 287615 (NCT00508833).
Study: NCT02324192

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasonography
Description: imaging findings

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasonography
Description: imaging findings
Study: NCT03834181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring evaluation by connected devices: Wristband activity tracker Garmin Vivosmart® 3, Fora® Scale 550, Terraillon® Tensioscreen, Pulse oximeter Nonin® 3230, thermometer Fora® IR20b
Description: All patients will be monitored before and after the bariatric surgery:~* During the preoperative preparation phase: weight, exercise, blood pressure and heart rate~* In the immediate post operative period: continuous monitoring of the heart rate with a telemetry system~* Prolonged follow-up: weight, exercise, blood pressure and heart rate
Study: NCT01527097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Drug: Atorvastatin 80 mg for 6 months following by 40 mg for additional 6 months once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin placebo
Description: Atorvastatin 80mg during 6 month and 40mg in additional 6 month period once daily.
Study: NCT02086253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-788 and/or BQ-123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-788 and/or BQ-123
Study: NCT04216459

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral lactobacillus probiotics plus intramuscular cholecalciferol
Description: According to leukocyte anti- sedimentation rate (LAR) result on day 1 patients will be classified into high risk for sepsis patients (LAR \< 15 %) and low risk for sepsis patients (LAR ≥ 15%) High risk sepsis patients will be randomly allocated into one of the 3 groups (sealed opaque envelops) to vitamin D plus probiotics intervention group (HR-DP) group. to vitamin C plus vitamin B intervention group (HR-CB) group. to control group (HR-C) group that does not receive any supplement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous vitamin C plus thiamine
Description: starting from day 1 in a dose of 1 gm vitamin C and 200 mg thiamine intravenous 4 times at 12-hour intervals for 48 hours
Study: NCT03689153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63733657
Description: Single ascending IV low, middle, and high dose of JNJ-63733657 will be administered in sequential cohorts. The progression to the next (higher) dose level is dependent on acceptable safety and tolerability profile of JNJ-63733657 obtained after dose administration of the current dose level. The length of time between dosing days of cohorts will be at least 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63733657
Description: Single ascending IV low, middle, and high dose of JNJ-63733657 will be administered in sequential cohorts. The progression to the next (higher) dose level is dependent on acceptable safety and tolerability profile of JNJ-63733657 obtained after dose administration of the current dose level. The length of time between dosing days of cohorts will be at least 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63733657
Description: Single ascending IV low, middle, and high dose of JNJ-63733657 will be administered in sequential cohorts. The progression to the next (higher) dose level is dependent on acceptable safety and tolerability profile of JNJ-63733657 obtained after dose administration of the current dose level. The length of time between dosing days of cohorts will be at least 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo intravenously.
Study: NCT03970694

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Since 2006, neoadjuvant chemoradiotherapy has been a recommendation as standard treatment for locally advanced rectal cancer, and has been widely applied to clinical use. As for locally advanced colon cancer, it still lacks evidence to support whether neoadjuvant chemoradiotherapy is a beneficial option.We recently reported clinical data about therapeutic effect of 60 unresectable locally advanced colon cancer cases and it was exciting. According to our results, through neoadjuvant chemoradiotherapy, R0 resection rate is 86%, local recurrence rate is 10.2%, 3-year OS and 5-year OS are 76.7% and 66.6%, respectively.Colorectal cancer diagnoses and treatment guidelines written by Chinses Society of Clinical Oncology (ver. 2017, 2018), suggested that neoadjuvant chemoradiotherapy was an optional treatment strategy or secondary recommended treatment strategy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin+capecitabine
Description: Colorectal cancer is one of the most common malignant tumors, the morbidity and mortality rate are both in rising trend. 10-23% newly diagnosed colon cancer is at locally advanced stage and surgical unresectable. For this subgroup, treatment guidelines recommend neoadjuvant chemotherapy with or without targeted therapy.

Intervention type: DRUG
Group type: OTHER
Intervention: oxaliplatin+capecitabine
Description: Colorectal cancer is one of the most common malignant tumors, the morbidity and mortality rate are both in rising trend. 10-23% newly diagnosed colon cancer is at locally advanced stage and surgical unresectable. For this subgroup, treatment guidelines recommend neoadjuvant chemotherapy with or without targeted therapy.
Study: NCT01309542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate
Description: Tablet were taken at a daily dose of 200 to 400 mg/day for a duration up to 10 months
Study: NCT01974492

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper leg vein harvesting
Description: Patients whose saphenous veins are harvested from upper legs.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lower leg vein harvesting
Description: Patients whose saphenous veins are harvested from lower legs.
Study: NCT02613650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162 and mFOLFIRI
Description: MEK162 in combination with mFOLFIRI in a 14 day cycle~MEK162 will be given single agent 6 day lead in and then will be given in combination with mFOLFIRI~mFOLFIRI Administered Day 1 of each cycle Irinotecan 180mg/m2 iv over 90 minutes on day 1 5-fluoruracil 1200mg/m2 continuous infusion for 48 hours (2400mg/m2 in 48 hours)~Followed by MEK162 - Taken twice daily orally on Days 1-12 of each cycle~Level -1: mFOLFIRI at 80% + MEK162 30 mg twice daily 1 week on and 1 week off Level 1: mFOLFIRI + MEK162 30 mg twice daily Level 2: mFOLFIRI + MEK162 45 mg twice daily
Study: NCT04424160

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP injection in the endometrium
Description: Within 5 days after the cessation of menstrual period, endometrial PRP procedure will be planned. Approximately 20 ml of blood sample will be collected under sterile conditions, and PRP will be prepared. The same day, within 2 hours of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into the endometrial region of the endometrium in several positions.On the same day after the procedure, the patient will be observed in the outpatient room and will be discharged on the same day.
Study: NCT00809666

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Automated blood pressure recording device Omron HEM 705CP
Description: All subsequent blood pressure recordings done using the automated device
Study: NCT02628236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid (ALA)
Description: 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BLU-U
Description: 10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2
Study: NCT01912742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Very-low calorie diet (VLCD)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low calorie diet (LCD)
Study: NCT03545763

Intervention type: OTHER
Intervention: Medicaid Expansion
Description: There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not

Intervention type: OTHER
Intervention: Medicaid Expansion
Description: There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
Study: NCT03107520

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intraoperative contrast-enhanced ultrasound (CEUS)
Description: An intraoperative CEUS of the dysplastic femoral head will be performed after surgical reduction of the femoral head and during placement of the spica cast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumason
Description: Administration of Lumason contrast agent to improve visualization of epiphyseal vascularity in the femoral head.
Study: NCT04609228

Intervention type: OTHER
Intervention: Non-acceptance of blood-transfusions
Description: Patients who do not accept blood products transfusions

Intervention type: OTHER
Intervention: Acceptance of blood-transfusions
Description: Patients who accept blood products transfusions
Study: NCT04056572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3139
Description: TQ-B3139 is competitive multi-target protein kinase inhibitor of Met/ALK/ROS.
Study: NCT00840086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: Subjects will receive bleeding preventive treatment (home treatment with self-injection i.v.) with turoctocog alfa at a dose of 20-40 IU/kg body weight every second day or 20-50 IU/kg body weight three times per week at the investigator's discretion.
Study: NCT01845012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily hemodialysis at low dialysate flow
Description: Daily hemodialysis at low dialysate flow during 3 months: 6 times 2h to 2h30 per week at a dialysate flow rate of 200 ml/min in order that the total duration of weekly dialysis is equivalent to the duration of weekly dialysis during the last 3 months of conventional hemodialysis. Other parameters of dialysis (dialysate, dialysis machine, generator, blood flow, anticoagulation) are the same as the reference period of conventional hemodialysis.
Study: NCT02970214

Intervention type: OTHER
Intervention: no intervention, only observational
Description: no intervention, only observational

Intervention type: OTHER
Intervention: no intervention, only observational
Description: no intervention, only observational
Study: NCT00833053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab 5 mg/kg body weight intravenous infusion given every 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab and methotrexate
Description: Infliximab 5 mg/kg body weight intravenous infusion (given every 8 weeks) plus methotrexate 7.5 mg orally (once weekly)
Study: NCT04425291

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4-valent HPV Vaccine
Description: Subjects received 3 doses of 4-valent HPV vaccine according to a 0, 2, 6-month schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9-valent HPV Vaccine
Description: Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GARDASIL®
Description: Subjects received 3 doses of GARDASIL® according to a 0, 2, 6-month schedule.
Study: NCT00540137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nevirapine
Description: 400mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atazanavir/ritonavir
Description: atazanavir 300 mg once daily ritonavir 100 mg once daily
Study: NCT00957528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Weekly im injections of 100 mg testosterone enanthate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Weekly im injections of 100 mg testosterone enanthate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Weekly IM injections of sesame oil.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weekly IM injections of sesame oil.
Study: NCT03717909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Valproate 200Mg E/C Tablet
Description: Treatment with twice-daily oral tablet(s)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Valproate matched placebo
Description: Treatment with twice-daily oral 200mg tablet(s)
Study: NCT05285241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidirectional stepping exercises
Description: These exercises included stepping of the legs in different directions i.e. sideways, sideways and forefoot (forward), sideways and heel (backward).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy group
Description: Conventional physiotherapy included a one-to-one range of motion exercises (10min), Strengthening exercises (10 min), Functional mat exercises (10 min), Stretching exercises (5 min), and Gait exercises (10 min)